CEO of Velabs Therapeutics.
Christoph is an experienced company executive and former venture capital manager in the fields of life sciences with special focus on drug development (small molecules and biologicals), diagnostics and instrumentation.
Before joining Velabs, he was CEO and Managing Director of different companies like Luxendo (light sheet microscopy), Acousia Therapeutics (inner ear drug development), Abeta (Alzheimer diagnostics) and EMBL Ventures (venture capital fund), being instrumental in company build-up, strategy implementation and financing up to successful M&A. He holds a Ph.D. in physics (structural biology) from the University of Heidelberg and did postdoctoral studies at the University of California, San Francisco (rational drug development). Christoph is an alumnus of the Max-Planck-Institute for Medical Research, Heidelberg.
Visit website: http://www.velabs-therapeutics.com/about-velabs/
See also: Velabs Therapeutics - Fast generation of functional therapeutic antibodies.
Christoph Antz News
Labiotech gathers feedback from European biotechs on Unity failure
Labiotech - 28-Aug-2020
General feeling that failures are bound to happen - but that their approaches can succeedRead more...